Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | DRD2 | P14416 | 1/20 | 0.83 |
| ▸ | DRD1 | P21728 | 1/20 | 0.83 |
| ▸ | HTR1B | P28222 | 1/20 | 0.83 |
| ▸ | HTR2A | P28223 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alnespirone SCHEMBL13532499 | 0.91 | HTR1A (1.00) | HTR1ADRD2DRD1HTR1BHTR2A | |
| Alnespirone SCHEMBL114478 | 0.91 | HTR1A (1.00) | HTR1ADRD2DRD1HTR1BHTR2A | |
| Alnespirone SCHEMBL29639699 | 0.91 | HTR1A (1.00) | HTR1ADRD2DRD1HTR1BHTR2A | |
| Alnespirone SCHEMBL29390957 | 0.90 | HTR1A (0.98) | HTR1ADRD2DRD1HTR1BHTR2A | |
| Alnespirone SCHEMBL29349572 | 0.90 | HTR1A (0.98) | HTR1ADRD2DRD1HTR1BHTR2A | |
| Alnespirone SCHEMBL114479 | 0.90 | HTR1A (0.98) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL13532497 | 0.90 | HTR1A (0.98) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL9304956 | 0.87 | HTR1A (0.81) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL9304776 | 0.86 | HTR1A (0.72) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL13532501 | 0.84 | HTR1A (0.89) | HTR1ADRD2DRD1HTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-5346916-A | FOR TREATING ANIMALS SUFFERING FROM DISORDERS OF THE SEROTONINERGIC SYSTEM | ADIR ET COMPAGNIE (FR) | 1994-09-13 | — | — | US | disclosed |
| US-5314907-A | 3-aminochroan compounds | ADIR ET COMPAGNIE (FR) | 1994-05-24 | — | — | US | disclosed |
| US-5273994-A | Also hydroxy- or alkyl ether-substituted | ADIR ET COMPAGNIE (FR) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885DRD2 242/4885DRD1 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.